Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 8:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Renal Impaired Clear all
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Evaluate PK and Safety of Proellex® in Females With Various Stages of Impaired Renal Function and Healthy Females

NCT00787618
View directory record Official record
Conditions
Renal Impairment
Interventions
50 mg Proellex
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 48 Years · Female only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
4
States / cities
Miami, Florida • Orlando, Florida • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2014 · Synced Jun 10, 2026, 8:21 PM EDT
Completed Phase 2 Interventional

Oxaliplatin With FOLFOX4 in Patients With Normal and Abnormal Renal Function

NCT00094965
View directory record Official record
Conditions
Gastrointestinal Cancer
Interventions
Oxaliplatin (SR96669)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 29, 2009 · Synced Jun 10, 2026, 8:21 PM EDT
Terminated Phase 4 Interventional Results available

A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairment

NCT03226899
View directory record Official record
Conditions
Gout, Chronic Kidney Disease (CKD)
Interventions
Lesinurad, XOI, Placebo, colchicine, corticosteroids
Drug
Lead sponsor
Ironwood Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
70
States / cities
Birmingham, Alabama • Tucson, Arizona • Covina, California + 59 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Jun 10, 2026, 8:21 PM EDT
Completed No phase listed Observational

Collection of Samples From Pregnant Women for the Evaluation of Preeclampsia (Pre-E) Biomarkers

NCT02780414
View directory record Official record
Conditions
Preeclampsia, Hypertension, Proteinuria, Thrombocytopenia, Renal Insufficiency, Impaired Liver Function, Pulmonary Edema
Interventions
Not listed
Lead sponsor
Progenity, Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
1,730 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
20
States / cities
Birmingham, Alabama • Aurora, Colorado • New Haven, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2022 · Synced Jun 10, 2026, 8:21 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study for AKB-6548 in Participants With Chronic Kidney Disease and Anemia

NCT01235936
View directory record Official record
Conditions
Anemia, Kidney Disease
Interventions
AKB-6548
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years to 79 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Augusta, Georgia • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 30, 2022 · Synced Jun 10, 2026, 8:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study To Investigate The Pharmacokinetics, Safety And Tolerability Of An Intravenous And Oral Form Of A Compound In Subjects With Varying Degrees Of Renal Impairment And Normal Renal Function

NCT00759564
View directory record Official record
Conditions
Pneumonia
Interventions
CP-70,429 and PF-03709270
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 85 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 10, 2016 · Synced Jun 10, 2026, 8:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Pharmacokinetics, Safety, and Tolerability of Intravenous ETX2514 and Sulbactam Administered Concurrently to Subjects With Various Degrees of Renal Impairment and Healthy Matched Control Subjects

NCT03310463
View directory record Official record
Conditions
Acinetobacter Baumannii Infection
Interventions
ETX2514SUL
Drug
Lead sponsor
Entasis Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
3
States / cities
Lakewood, Colorado • Miami, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 13, 2018 · Synced Jun 10, 2026, 8:21 PM EDT
Completed Phase 3 Interventional Results available

Safety and Diagnostic Efficacy of Mangoral in Participants With Focal Liver Lesions and Reduced Kidney Function

NCT04119843
View directory record Official record
Conditions
Known or Suspected Focal Liver Lesions, Severe Renal Impairment
Interventions
Mangoral
Drug
Lead sponsor
Ascelia Pharma AB
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
14
States / cities
Scottsdale, Arizona • Los Angeles, California • Stanford, California + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Jun 10, 2026, 8:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Glasdegib Renal Impairment Study

NCT03596567
View directory record Official record
Conditions
Renal Impairment
Interventions
Glasdegib single 100 mg dose in normal healthy subjects, Glasdegib single 100 mg dose in moderate renal impairment subjects, Glasdegib single 100 mg dose in severe renal impairment subjects
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
3
States / cities
Miami, Florida • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Jun 10, 2026, 8:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study of PK and Safety of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Subjects With Various Degrees Of Renal Function

NCT04178577
View directory record Official record
Conditions
Renal Impairment
Interventions
Tebipenem pivoxil hydrobromide (TBPM-PI-HBr)
Drug
Lead sponsor
Spero Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Nov 26, 2020 · Synced Jun 10, 2026, 8:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase 1 Study of PK and Safety of HM15912 (Sonefpeglutide) in Subjects With Normal and Severe Kidney Function

NCT05711381
View directory record Official record
Conditions
Renal Impairment
Interventions
HM15912
Drug
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
4
States / cities
Tustin, California • Miami, Florida • Miami Lakes, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Jun 10, 2026, 8:21 PM EDT
Completed Phase 1 Interventional Results available

An Open-Label Pharmacokinetics and Safety Study of Talazoparib

NCT02997163
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
Talazoparib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
7
States / cities
Fort Wayne, Indiana • Detroit, Michigan • Farmington Hills, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Jun 10, 2026, 8:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of MK-8527 in Participants With Moderate and Severe Renal Impairment (MK-8527-008)

NCT06295796
View directory record Official record
Conditions
Renal Impairment
Interventions
MK-8527
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Jun 10, 2026, 8:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Normal Renal Function or With Severe Renal Impairment

NCT03443063
View directory record Official record
Conditions
Renal Impairment
Interventions
Lemborexant
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 79 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 11, 2020 · Synced Jun 10, 2026, 8:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics and Safety of VIR-2218

NCT05844228
View directory record Official record
Conditions
Renal Impairment
Interventions
VIR-2218
Drug
Lead sponsor
Vir Biotechnology, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
3
States / cities
Rialto, California • Miami Lakes, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Jun 10, 2026, 8:21 PM EDT
Completed Phase 1 Interventional

A Pharmacokinetics and Safety Study in Subjects With Renal Impairment

NCT01452828
View directory record Official record
Conditions
Renal Impairment
Interventions
TR-701 FA single infusion, TR-701 FA
Drug
Lead sponsor
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Orlando, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 2, 2016 · Synced Jun 10, 2026, 8:21 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal Impairment

NCT02827708
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
semaglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
60
States / cities
Tuscumbia, Alabama • Bermuda Dunes, California • Concord, California + 52 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2020 · Synced Jun 10, 2026, 8:21 PM EDT
Terminated Phase 1 Interventional Results available

A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease

NCT05487040
View directory record Official record
Conditions
COVID-19
Interventions
PF-07321332 (nirmatrelvir)/ritonavir
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
52
States / cities
Huntsville, Alabama • Granada Hills, California • Inglewood, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2024 · Synced Jun 10, 2026, 8:21 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Single Dose Study Investigating the Elimination as Well as the Tolerability of PD 0332334 in Healthy Subjects as Compared to Patients With Impaired Kidney Function.

NCT00721422
View directory record Official record
Conditions
Renal Insufficiency, Pharmacokinetics
Interventions
PD 0332334
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
2
States / cities
Cypress, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 16, 2010 · Synced Jun 10, 2026, 8:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Severe Renal Impairment Compared to Matched Healthy Participants.

NCT07032272
View directory record Official record
Conditions
Autoimmune and Chronic Inflammatory Diseases
Interventions
remibrutinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
4
States / cities
Miami, Florida • Miami Lakes, Florida • Orlando, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Jun 10, 2026, 8:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of ASP0367 in People With Kidneys That do Not Work Well and in Healthy People

NCT05117294
View directory record Official record
Conditions
Renal Impairment, Healthy Volunteers
Interventions
Bocidelpar
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
4
States / cities
Anniston, Alabama • Rialto, California • Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2024 · Synced Jun 10, 2026, 8:21 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Investigation of the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Opemalirsen (AZD2373)

NCT07154901
View directory record Official record
Conditions
Renal Impairment
Interventions
Opemalirsen (AZD2373)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jun 10, 2026, 8:21 PM EDT
Completed Not applicable Interventional Results available

A Study to Assess the Tolerability and Efficacy of AKST1210 in Patients on Hemodialysis With Cognitive Impairment

NCT04527328
View directory record Official record
Conditions
Cognitive Impairment, End Stage Renal Disease
Interventions
AKST1210, Sham Control (No Intervention), Hemodialysis
Device · Other · Procedure
Lead sponsor
Alkahest, Inc.
Industry
Eligibility
40 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
4
States / cities
Granada Hills, California • Northridge, California • Orlando, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2022 · Synced Jun 10, 2026, 8:21 PM EDT
Completed Phase 4 Interventional

Dapagliflozin Treatment in Type 2 Diabetes

NCT04620590
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Impaired Renal Function
Interventions
Dapagliflozin 10 MG [Farxiga]
Drug
Lead sponsor
Emerald Clinical Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Jun 10, 2026, 8:21 PM EDT